CY1106616T1 - Συνθεσεις οι οποιες αναστελλουν τον πολλαπλασιασμο λειων μυων και μεθοδος για τη διαγνωση της αρτηριοσκληρωσης - Google Patents
Συνθεσεις οι οποιες αναστελλουν τον πολλαπλασιασμο λειων μυων και μεθοδος για τη διαγνωση της αρτηριοσκληρωσηςInfo
- Publication number
- CY1106616T1 CY1106616T1 CY20071100696T CY071100696T CY1106616T1 CY 1106616 T1 CY1106616 T1 CY 1106616T1 CY 20071100696 T CY20071100696 T CY 20071100696T CY 071100696 T CY071100696 T CY 071100696T CY 1106616 T1 CY1106616 T1 CY 1106616T1
- Authority
- CY
- Cyprus
- Prior art keywords
- apm1
- expression
- atherosclerosis
- compositions
- determination
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 title 1
- 208000011775 arteriosclerosis disease Diseases 0.000 title 1
- 230000035755 proliferation Effects 0.000 title 1
- 210000002460 smooth muscle Anatomy 0.000 title 1
- 102100031786 Adiponectin Human genes 0.000 abstract 3
- 201000001320 Atherosclerosis Diseases 0.000 abstract 3
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 abstract 3
- 208000008589 Obesity Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 102100024735 Resistin Human genes 0.000 abstract 1
- 108010047909 Resistin Proteins 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 238000011835 investigation Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000008477 smooth muscle tissue growth Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4704—Inhibitors; Supressors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
Η εφεύρεση παρέχει όχι μόνο μια ανασταλτική της ανάπτυξης λείων μυών σύνθεση και μια σύνθεση για αναστολή της έκφρασης μορίων προσκόλλησης σε αγγειακά ενδοθηλιακά κύτταρα, με την κάθε μία να περιλαμβάνει τον ειδικό για λιπώδη ιστό εκκριτικό παράγοντα apM1 ως ένα δραστικό συστατικό, αλλά επίσης μια μέθοδο για διάγνωση της αρτηριοσκλήρωσης η οποία περιλαμβάνει τον προσδιορισμό του apM1 σε ένα δείγμα, ένα αντίσωμα ενάντια στον apM1, και ένα διαγνωστικό κυτίο για αρτηριοσκλήρωση το οποίο περιλαμβάνει το αντίσωμα ως ένα δραστικό συστατικό, τα οποία όλα συνεισφέρουν στη διασάφηση γονιδίων που σχετίζονται με παχυσαρκία και αντίστοιχων προϊόντων έκφρασης τα οποία είναι χρήσιμα για την αιτιολογική διερεύνηση και διαπίστωση θεραπευτικών μεθόδων για διάφορες νόσους που σχετίζονται με παχυσαρκία, ειδικότερα αρτηριοσκλήρωση συμπεριλαμβάνοντας στηθάγχη και έμφραγμα του μυοκαρδίου. Χρησιμοποιώντας την πληροφορία που ελήφθη κατ' αυτόν τον τρόπο, θεραπευτικές και διαγνωστικές μέθοδοι για διάφορες νόσους μπορεί να καταρτιστούν.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29756997 | 1997-10-29 | ||
PCT/JP1998/004862 WO1999021577A1 (fr) | 1997-10-29 | 1998-10-27 | Compositions inhibant la proliferation des muscles lisses, procede de diagnostic de l'arteriosclerose et trousses correspondantes |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1106616T1 true CY1106616T1 (el) | 2012-01-25 |
Family
ID=17848257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071100696T CY1106616T1 (el) | 1997-10-29 | 2007-05-22 | Συνθεσεις οι οποιες αναστελλουν τον πολλαπλασιασμο λειων μυων και μεθοδος για τη διαγνωση της αρτηριοσκληρωσης |
Country Status (10)
Country | Link |
---|---|
US (3) | US6461821B1 (el) |
EP (1) | EP1033134B8 (el) |
JP (2) | JP3538711B2 (el) |
AT (1) | ATE360433T1 (el) |
CY (1) | CY1106616T1 (el) |
DE (2) | DE69837678T2 (el) |
DK (1) | DK1033134T3 (el) |
ES (1) | ES2285786T3 (el) |
PT (1) | PT1033134E (el) |
WO (1) | WO1999021577A1 (el) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2767135B1 (fr) * | 1997-08-06 | 2002-07-12 | Genset Sa | Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes |
ATE397064T1 (de) | 1998-11-04 | 2008-06-15 | Serono Genetics Inst Sa | Genomische und vollständige cdna sequenzen von menschlichem adipozyten spezifischem apm1 und biallelische marker davon |
ES2323445T3 (es) | 1999-02-10 | 2009-07-16 | Serono Genetics Institute S.A. | Marcadores polimorficos del gen lsr. |
KR20010102130A (ko) | 1999-02-19 | 2001-11-15 | 리스 데브라 케이. | 지혈 및 면역기능에 사용하기 위한 억제제 |
US6544946B1 (en) | 1999-02-19 | 2003-04-08 | Zymogenetics, Inc. | Inhibitors for use in hemostasis and immune function |
JP4689787B2 (ja) * | 1999-04-12 | 2011-05-25 | 住友化学株式会社 | 腹腔内脂肪組織量の分析方法 |
WO2001032868A1 (en) * | 1999-11-04 | 2001-05-10 | Genset | Apm1 biallelic markers and uses thereof |
US7338787B2 (en) | 2000-01-14 | 2008-03-04 | Serono Genetics Institute S.A. | Nucleic acids encoding OBG3 globular head and uses thereof |
US6579852B2 (en) | 2000-01-14 | 2003-06-17 | Genset S.A. | OBG3 globular head and uses thereof for decreasing body mass |
US6566332B2 (en) | 2000-01-14 | 2003-05-20 | Genset S.A. | OBG3 globular head and uses thereof for decreasing body mass |
US6989367B2 (en) | 2000-01-14 | 2006-01-24 | Genset S.A. | OBG3 globular head and uses thereof |
US20020058617A1 (en) | 2000-01-14 | 2002-05-16 | Joachim Fruebis | OBG3 globular head and uses thereof for decreasing body mass |
EP1248849B1 (en) * | 2000-01-14 | 2008-08-20 | Serono Genetics Institute S.A. | Obg3 globular head and uses thereof for decreasing body mass |
US7405193B2 (en) * | 2000-05-31 | 2008-07-29 | Serono Genetics Institute S.A. | Use of Acrp30 globular head to promote increases in muscle mass and muscle differentiation |
JP2004521930A (ja) * | 2001-03-14 | 2004-07-22 | オクラホマ メディカル リサーチ ファウンデーション | アジポネクチンの投与により脂肪を減少させるための方法。 |
WO2003009862A1 (en) * | 2001-07-20 | 2003-02-06 | Genset S.A. | Agonists and antagonists of modumet for use in the treatment of metabolic disorders |
WO2003009864A1 (en) * | 2001-07-23 | 2003-02-06 | Genset S.A. | Agonists and antagonists of disomet for the treatment of metabolic disorders |
WO2003009861A1 (en) * | 2001-07-24 | 2003-02-06 | Genset S.A. | Agonists and antagonists of metabolix in the treatment of metabolic disorders |
WO2003009865A1 (en) * | 2001-07-25 | 2003-02-06 | Genset S.A. | Agonists and antagonists of energen for use in the treatment of metabolic disorders |
WO2003009863A1 (en) * | 2001-07-26 | 2003-02-06 | Genset S.A. | Agonists and antagonists of cofoxin for use in the treatment of metabolic disorders |
WO2003011325A1 (en) * | 2001-07-27 | 2003-02-13 | Genset S.A. | Agonists and antagonists of moceptin for the treatment of metabolic disorders |
WO2003011323A1 (en) * | 2001-07-30 | 2003-02-13 | Genset S.A. | Agonists and antagonists of contabix for use in the treatment of metabolic disorders |
WO2003011321A1 (en) * | 2001-07-31 | 2003-02-13 | Genset S.A. | Agonists and antagonists of cobesin for the treatment of metabolic disorders |
US20050054565A1 (en) * | 2001-07-31 | 2005-03-10 | John Lucas | Agonists and antagonists of moxifin for the treatment of metabolic disorders |
US20070129291A1 (en) * | 2001-08-01 | 2007-06-07 | Genset S.A. | Genobix agonists and antagonists for use in the treatment of metabolic disorders |
WO2003011318A1 (en) * | 2001-08-01 | 2003-02-13 | Genset S.A. | Agonists and antagonists of famoset for use in the treatment of metabolic disorders |
EP1418934A1 (en) | 2001-08-02 | 2004-05-19 | Genset S.A. | Xobesin agonists and antagonists for the treatment of metabolic disorders |
WO2003011320A1 (en) * | 2001-08-02 | 2003-02-13 | Genset S.A. | Agonists and antagonists of obesingen for the treatment of metabolic disorders |
WO2003011322A1 (en) * | 2001-08-02 | 2003-02-13 | Genset S.A. | Agonists and antagonists of genoxin for use in the treatment of metabolic disorders |
WO2003013580A1 (en) * | 2001-08-03 | 2003-02-20 | Genset S.A. | Tr xidatin agonists and antagonists treatment of metabolic disorders |
WO2003013579A1 (en) * | 2001-08-03 | 2003-02-20 | Genset S.A. | Lypergix agonists and antagonists for use in the treatment of metabolic disorders |
WO2003013581A1 (en) * | 2001-08-03 | 2003-02-20 | Genset S.A. | Agonists and antagonists of genceptin for the treatment of metabolic disorders |
WO2003013582A1 (en) * | 2001-08-06 | 2003-02-20 | Genset S.A. | Genoxit agonists and antagonists for use in the treatment of metabolic disorders |
WO2003013578A1 (en) * | 2001-08-07 | 2003-02-20 | Genset S.A. | Omoxin agonists and antagonists for use in the treatment of metabolic disorders |
WO2003013585A1 (en) * | 2001-08-08 | 2003-02-20 | Genset S.A. | Mifaxin agonists and antagonists for use in the treatment of metabolic |
WO2003013604A2 (en) * | 2001-08-09 | 2003-02-20 | Genset S.A. | Migenix agonists and antagonists for use in the treatment of metabolic disorders |
WO2003013584A1 (en) * | 2001-08-09 | 2003-02-20 | Genset S.A. | Xafinix agonists and antagonists for use in the treatment of metabolic disorders |
WO2003013583A1 (en) * | 2001-08-10 | 2003-02-20 | Genset S.A. | Faxigen agonists and antagonists in the treatment of metabolic disorders |
CA2459489C (en) * | 2001-08-17 | 2010-02-02 | Rebio Gen, Inc. | Method for diagnosing or monitoring carbohydrate metabolism disorders |
WO2003026695A1 (en) * | 2001-09-21 | 2003-04-03 | Genset S.A. | Agonists and antagonists of cylixin for the treatment of metabolic disorders |
WO2003041738A1 (en) * | 2001-11-15 | 2003-05-22 | Genset S.A. | Treatment of metabolic disorders with xitar agonists and antagonists |
WO2003041730A1 (en) * | 2001-11-16 | 2003-05-22 | Genset S.A. | Ditacin agonists and antagonists for use in the treatment of metabolic disorders |
US20060089311A1 (en) * | 2001-11-28 | 2006-04-27 | Deno Dialvnas | Agonists and antagonists of ryzn for the treatment of metabolic disorders |
US7344843B2 (en) | 2001-11-29 | 2008-03-18 | Serono Genetics Institute S.A. | Agonists and antagonists of prolixin for the treatment of metabolic disorders |
WO2003047615A1 (en) * | 2001-12-05 | 2003-06-12 | Genset S.A. | Dexar agonists and antagonists for use in the treatment of metabolic disorders |
AU2002339683A1 (en) * | 2001-12-05 | 2003-06-17 | Genset S.A. | Agonist and antagonists of redax for the treatment of metabolic disorders |
AU2002339681A1 (en) * | 2001-12-12 | 2003-06-23 | Genset S.A. | Agonists and antagonists of glucomin for the treatment of metabolic disorders |
AU2002339685A1 (en) * | 2001-12-13 | 2003-06-23 | Genset S.A. | Agonists and antagonists of oxifan for the treatment of metabolic disorders |
WO2003049756A1 (en) * | 2001-12-13 | 2003-06-19 | Genset S.A. | Glucomin agonists and antagonists for use in the treatment of metabolic disorders |
AU2002339682A1 (en) * | 2001-12-13 | 2003-06-23 | Genset S.A. | Emergen agonists and antagonists for use in the treatment of metabolic disorders |
AU2002339688A1 (en) * | 2001-12-14 | 2003-06-30 | Genset S.A. | Glucoset agonists and antagonists for use in the treatment of metabolic disorders |
WO2003055509A1 (en) * | 2001-12-26 | 2003-07-10 | Genset S.A. | Agonists and antagonists of bromix for the treatment of metabolic disorders |
NZ534699A (en) * | 2002-01-18 | 2008-12-24 | Protemix Corp Ltd | Glycoisoforms of adiponectin and uses thereof |
EP1537875B1 (en) * | 2002-05-24 | 2009-08-26 | Japan Science and Technology Agency | C-terminal globular domain of adiponectin for use in the treatment of arteriosclerosis |
JP4509933B2 (ja) * | 2003-03-24 | 2010-07-21 | 三菱化学メディエンス株式会社 | アディポネクチン分析用ラテックス試薬及びアディポネクチン分析方法 |
GB0312122D0 (en) * | 2003-05-27 | 2003-07-02 | Pharmagene Lab Ltd | Therapeutic method |
WO2005103720A1 (en) * | 2004-03-29 | 2005-11-03 | Medstar Research Institute, Inc. | Methods of diagnosing cardiovascular disease |
DE102004042530B4 (de) * | 2004-09-02 | 2006-10-19 | Mosaiques Diagnostics And Therapeutics Ag | Verfahren zur Diagnose von Arteriosklerose |
AU2005312435A1 (en) * | 2004-12-10 | 2006-06-15 | Philera New Zealand Limited | Glyponectin (glycosylated adiponectin) for the treatment of diseases and conditions |
US7592423B2 (en) * | 2005-01-07 | 2009-09-22 | Xencor, Inc. | Globular adiponectin variants |
US7678886B2 (en) * | 2005-01-07 | 2010-03-16 | Xencor, Inc. | Pharmaceutical compositions of adiponectin variants and methods of storage |
CA2585733A1 (en) * | 2005-01-07 | 2006-07-13 | Arthur J. Chirino | Adiponectin variants |
US7749956B2 (en) * | 2005-01-07 | 2010-07-06 | Xencor, Inc. | Method of treatment using adiponectin variants |
US20070054359A1 (en) * | 2005-07-11 | 2007-03-08 | Jonathan Zalevsky | Rational Chemical Modification of Adiponectin Variants |
US8636995B2 (en) * | 2006-08-31 | 2014-01-28 | Cardiac Pacemakers, Inc. | Methods and devices to regulate stem cell homing |
US20080058922A1 (en) * | 2006-08-31 | 2008-03-06 | Cardiac Pacemakers, Inc. | Methods and devices employing vap-1 inhibitors |
US8372399B2 (en) * | 2006-08-31 | 2013-02-12 | Cardiac Pacemakers, Inc. | Bispecific antibodies and agents to enhance stem cell homing |
US9061076B2 (en) | 2007-05-25 | 2015-06-23 | North Carolina State University | Viral nanoparticle cell-targeted delivery platform |
CN101932728B (zh) * | 2007-11-30 | 2013-06-19 | 西门子医疗保健诊断公司 | 脂连蛋白受体片段和使用方法 |
US8268604B2 (en) * | 2007-12-20 | 2012-09-18 | Abbott Point Of Care Inc. | Compositions for forming immobilized biological layers for sensing |
US8241697B2 (en) | 2007-12-20 | 2012-08-14 | Abbott Point Of Care Inc. | Formation of immobilized biological layers for sensing |
EP2088156A1 (en) * | 2008-02-08 | 2009-08-12 | Institut Pasteur | Use of adiponectin for the diagnosis and/or treatment of presbycusis |
TW201500053A (zh) | 2008-08-27 | 2015-01-01 | Otsuka Pharma Co Ltd | 用於治療肺部疾病之藥劑(二) |
ES2693165T3 (es) | 2009-04-23 | 2018-12-07 | Siemens Healthcare Diagnostics Inc. | Formas monoméricas y diméricas de fragmentos de receptores de adiponectina y métodos de uso |
MX2012002766A (es) * | 2009-09-03 | 2012-04-02 | Genentech Inc | Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide. |
KR101868620B1 (ko) | 2015-08-12 | 2018-07-23 | 중앙대학교 산학협력단 | Fgf12를 이용한 혈관 평활근세포 증식성 질환의 진단, 예방 또는 치료용 조성물 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869330A (en) * | 1995-06-05 | 1999-02-09 | Whitehead Institute For Biomedical Research | DNA encoding a novel serum protein produced exclusively in adipocytes |
US5858682A (en) * | 1996-08-02 | 1999-01-12 | Pharmingen | E2A/pbx1 fusion protein specific monoclonal antibodies |
JP4253815B2 (ja) * | 1997-10-29 | 2009-04-15 | 大塚製薬株式会社 | 平滑筋増殖抑制組成物、動脈硬化症予防及び治療組成物及び血管再建術後の再狭窄予防及び治療組成物 |
-
1998
- 1998-10-27 JP JP2000517735A patent/JP3538711B2/ja not_active Expired - Lifetime
- 1998-10-27 DE DE69837678T patent/DE69837678T2/de not_active Expired - Lifetime
- 1998-10-27 US US09/530,423 patent/US6461821B1/en not_active Expired - Lifetime
- 1998-10-27 DE DE98950411T patent/DE98950411T1/de active Pending
- 1998-10-27 ES ES98950411T patent/ES2285786T3/es not_active Expired - Lifetime
- 1998-10-27 AT AT98950411T patent/ATE360433T1/de active
- 1998-10-27 PT PT98950411T patent/PT1033134E/pt unknown
- 1998-10-27 WO PCT/JP1998/004862 patent/WO1999021577A1/ja active IP Right Grant
- 1998-10-27 EP EP98950411A patent/EP1033134B8/en not_active Expired - Lifetime
- 1998-10-27 DK DK98950411T patent/DK1033134T3/da active
-
2002
- 2002-07-08 US US10/189,493 patent/US20030166551A1/en not_active Abandoned
-
2005
- 2005-04-04 US US11/097,334 patent/US7285275B2/en not_active Expired - Fee Related
-
2007
- 2007-05-22 CY CY20071100696T patent/CY1106616T1/el unknown
-
2008
- 2008-11-05 JP JP2008284353A patent/JP4859904B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20050163779A1 (en) | 2005-07-28 |
JP4859904B2 (ja) | 2012-01-25 |
ATE360433T1 (de) | 2007-05-15 |
WO1999021577A1 (fr) | 1999-05-06 |
DK1033134T3 (da) | 2007-07-16 |
EP1033134A4 (en) | 2004-10-13 |
DE69837678D1 (de) | 2007-06-06 |
DE69837678T2 (de) | 2007-12-27 |
US6461821B1 (en) | 2002-10-08 |
US20030166551A1 (en) | 2003-09-04 |
DE98950411T1 (de) | 2005-10-20 |
JP3538711B2 (ja) | 2004-06-14 |
EP1033134B8 (en) | 2007-09-19 |
US7285275B2 (en) | 2007-10-23 |
ES2285786T3 (es) | 2007-11-16 |
PT1033134E (pt) | 2007-07-11 |
JP2009079064A (ja) | 2009-04-16 |
EP1033134A1 (en) | 2000-09-06 |
EP1033134B1 (en) | 2007-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1106616T1 (el) | Συνθεσεις οι οποιες αναστελλουν τον πολλαπλασιασμο λειων μυων και μεθοδος για τη διαγνωση της αρτηριοσκληρωσης | |
Li et al. | Inhibition of the Bloom's and Werner's syndrome helicases by G-quadruplex interacting ligands | |
DE69824004D1 (de) | Verfahren zur quantitativen bestimmung der genexpression mit hilfe der multiplexen competitiven reversen-transkriptase polymerase kettenreaktion | |
DE60040335D1 (de) | Derivatisierte nukleinsäuren und deren verwendung | |
WO2003057851A3 (en) | Binding proteins as biosensors | |
NO20021974D0 (no) | Fargemerkede imidazokinolinforbindelser | |
DE69720274D1 (de) | Anzeige des auftretens von herzschlägen | |
ATE269416T1 (de) | Verwendung von vereinigten sonden zur genetischen analyse | |
DE69839250D1 (de) | Verbesserte elektrochemische biosensor-teststreifen | |
WO2002089657A3 (en) | Diagnostic markers of acute coronary syndromes and methods of use thereof | |
DE60040677D1 (de) | Verbessertes toxizität-screening verfahren | |
DE69808274D1 (de) | Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie | |
DE69814848D1 (de) | Untersuchung von nukleotiden in loesung mit hilfe von pna-sonden | |
Morano et al. | Expression of myosin heavy and light chains and phosphorylation of the phosphorylatable myosin light chain in the heart ventricle of the European hamster during hibernation and in summer | |
TR199700834T1 (xx) | 1-Aril-2-Akilamino ethan bile�ikleri ve bunlar�n n�rokinin olarak �zellikle n�rokinin 1 has�mlar� olarak kullan�mlar�. | |
DK1238284T3 (da) | Diagnostisk bestemmelse af slagtilfælde | |
ATE302413T1 (de) | Schnelle bestimmung des verhältnisses von biologischen molekülen | |
DK1791973T3 (da) | DOT1-histonmethyltransferaser som et target til at identificere terapeutiske midler mod leukæmi | |
HUP0203408A2 (hu) | Eljárás hiperlipémia elleni preventív vagy terápiás hatóanyag tesztelésére | |
WO2004002984A3 (fr) | Composes de maleimides marques, leur procede de preparation et leur utilisation pour le marquage de macromolecules | |
DE69941690D1 (de) | Methoden, testsätze und kompositionen zur detektion und quantifizierung von zielsequenzen | |
ATE256120T1 (de) | Reagentien für cyp2d fluoreszenztest | |
CY1106833T1 (el) | Ενας κινητηρας πολυνουκλεοτιδιου, ενα συστημα κινητηρα, η παρασκευη και οι χρησεις τους | |
Chakraborti et al. | Oxidative Stress in Heart Diseases | |
NO20004753L (no) | Fluorescent assay for topoisomerase-inhibitorer |